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Introduction: Various methods and devices have been described for cooling after cardiac arrest, but the ideal
cooling method remains unclear. The aim of this study was to compare the neurological outcomes, efficacies and
adverse events of surface and endovascular cooling techniques in cardiac arrest patients.
Methods: We performed a multicenter, retrospective, registry-based study of adult cardiac arrest patients treated
with therapeutic hypothermia presenting to 24 hospitals across South Korea from 2007 to 2012. We included patients
who received therapeutic hypothermia using overall surface or endovascular cooling devices and compared the
neurological outcomes, efficacies and adverse events of both cooling techniques. To adjust for differences in the
baseline characteristics of each cooling method, we performed one-to-one matching by the propensity score.
Results: In total, 803 patients were included in the analysis. Of these patients, 559 underwent surface cooling, and
the remaining 244 patients underwent endovascular cooling. In the unmatched cohort, a greater number of adverse
events occurred in the surface cooling group. Surface cooling was significantly associated with a poor neurological
outcome (cerebral performance category 3–5) at hospital discharge (p = 0.01). After propensity score matching, surface
cooling was not associated with poor neurological outcome and hospital mortality [odds ratio (OR): 1.26, 95%
confidence interval (CI): 0.81-1.96, p = 0.31 and OR: 0.85, 95% CI: 0.55-1.30, p = 0.44, respectively]. Although
surface cooling was associated with an increased incidence of adverse events (such as overcooling, rebound
hyperthermia, rewarming related hypoglycemia and hypotension) compared with endovascular cooling, these
complications were not associated with surface cooling using hydrogel pads.
Conclusions: In the overall matched cohort, no significant difference in neurological outcomes and hospital
morality was observed between the surface and endovascular cooling methods.Introduction
The International Liaison Committee on Resuscitation
recommends the cooling of unconscious patients who
present after having been resuscitated from out-of-
hospital cardiac arrest (OHCA) at a temperature of 32
to 34°C for 12 to 24 hours [1,2]. Various methods, such
as surface and core cooling, and various devices are
described for administration of this therapy. Surface* Correspondence: ohjoosuk@gmail.com
1Department of Emergency Medicine, College of Medicine, The Catholic
University of Korea, 222, Banpodaero, Seocho-gu, Seoul, Korea 137-701
Full list of author information is available at the end of the article
© 2015 Oh et al.; licensee BioMed Central. Thi
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.cooling methods include ice-pack application and water-
circulating blankets/wraps/caps/helmets/gel pads [3-6].
Cold intravenous infusion and cooling with endovascular
catheters or extracorporeal membrane oxygenation are
examples of core cooling methods [7-11].
Among these methods, ice-pack application or cold
fluid infusion are performed by staff without the aid of
temperature feedback regulation and are currently used
as adjuvant cooling. Surface cooling techniques that
utilize automatic temperature feedback devices are gen-
erally considered less expensive and are the most widely
used method. An additional widespread cooling methods is an Open Access article distributed under the terms of the Creative
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exchange catheter placed in the vena cava ensures tight
control of the core temperature by a temperature-guided
control unit. The control unit automatically steers the
cooling process as well as the maintenance and rewarm-
ing phase, and this unit has demonstrated improved
temperature control. However, consensus has not been
achieved regarding the ideal method for therapeutic
hypothermia (TH). Several studies have compared cool-
ing methods in TH after the return of spontaneous cir-
culation [12-14]. However, these studies were limited
due to few, uncontrolled data or a focus on comparisons
between specific devices, thus not demonstrating a
difference between surface and endovascular cooling
techniques.
The aim of this study was to compare overall surface
cooling methods with endovascular cooling methods
with regard to the neurological outcome, cooling efficacy
and adverse events of TH after cardiac arrest.
Materials and methods
Study design
This was a multicenter, retrospective, observational,
registry-based study using the Korean Hypothermia
Network registry data. The Korean Hypothermia Network,
a multicenter clinical research consortium for TH in
South Korea, was organized in 2011. Korean Hypothermia
Network investigators collected data on adult (≥18 years)
OHCA patients who received TH in 24 teaching hospitals
in South Korea from 2007 to 2012. Patients who experi-
enced traumatic cardiac arrest were excluded. The data
form, the standard definitions of 87 variables and the
registration manual were developed by literature review
and the consensus of the study investigators. The registry
data were collected by medical chart or electronic medical
record reviews. The collected data at each hospital were
verified for completeness by the site principal investigator
and were recorded in a web-based data registration system
[15] by the site clinical research coordinator. A data man-
ager and three clinical research associates monitored and
regularly reviewed data quality. The site principal investi-
gators or site clinical research coordinators were contacted
through the query function in the system or directly by
telephone to clarify the data.
The institutional review board of each institution
approved the study protocol before data collection
(Additional file 1). Informed consent was waived be-
cause of the retrospective nature of the study.
Study patients and variables
This study included patients who received TH using
surface or endovascular cooling devices equipped with
an automatic temperature feedback system. Cooling
methods without an automatic temperature feedbacksystem such as a simple cooling mattress, extracorporeal
membrane oxygenation, cold saline infusion or ice-pack
application were included in the study only when they
were combined with an automatic temperature feedback
device. In contrast, patients who received both types of
cooling methods (that is, surface and endovascular) were
excluded from this study. Patients who received TH by
surface cooling methods, such as hydrogel pads, body
wraps and other mattresses, were assigned to the surface
cooling group, whereas those who received TH via endo-
vascular cooling catheter were assigned to the endovas-
cular cooling group.
Data included covariates, such as basic demographics,
resuscitation variables and post-resuscitation variables.
Given that facilities with high volumes of TH cases
might demonstrate significantly better outcomes for
OHCA patients than those with low volumes [16], the
TH volumes of hospitals in the study period were evalu-
ated. Neurological outcomes were assessed just before
hospital discharge and were categorized according to the
Glasgow–Pittsburgh Cerebral Performance Categories
[17]. Variables of cooling efficacy included the induction
time (estimated time from the start of cooling to the tar-
get temperature) and the rewarming time (estimated time
from the start of rewarming to achieving the normo-
temperature). Adverse events related to the cooling phase
included overcooling (<32°C), bradycardia (<40 beats/
minute), tachyarrhythmia, hypokalemia (<3.0 mEq/l),
hyperglycemia (>180 mg/dl), bleeding and hypotension.
Rebound hyperthermia (>38°C), arrhythmia, hyperkalemia
(>5.0 mEq/l), hypoglycemia (<80 mg/dl), bleeding and
hypotension were recorded in the rewarming-related ad-
verse events. Tachyarrhythmia during cooling was defined
as newly developed tachyarrhythmia during cooling,
except for sinus tachycardia. Bleeding was defined
as bleeding at any site associated with cooling and
rewarming. Hypotension was defined as a systolic blood
pressure <90 mmHg or mean arterial pressure <60 mmHg
for at least 30 minutes or as the need for supportive mea-
sures to maintain a systolic blood pressure >90 mmHg or
mean arterial pressure >60 mmHg during cooling and
rewarming. Sepsis was defined as a clinical syndrome char-
acterized by the presence of both infection and a systemic
inflammatory response syndrome. Pneumonia was defined
by the following four findings: new or progressive consoli-
dation on the chest radiograph, fever, leukocytosis and the
presence of purulent tracheobronchial secretions.
Outcome measures
The primary outcome was a comparison of the propor-
tion of patients who had a poor neurological outcome
(Cerebral Performance Categories 3 to 5) at discharge.
The secondary outcomes were comparisons of the
proportion of hospital mortality, induction time and
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during cooling, rewarming and critical care. To adjust for
differences in the baseline characteristics of each group,
we performed one-to-one matching using the propensity
score. Finally, the outcomes were reevaluated in the pro-
pensity score matched cohort.
Statistical analysis
Categorical variables are presented as the counts and
percentage and were compared using the chi-square test
or Fisher’s exact test, where appropriate. The normality
of the continuous variables was verified by the Shapiro–
Wilk test. Thereafter, variables were expressed as the
mean ± standard deviation and were compared using
Student’s t test, after confirming homogeneity of vari-
ance with Levene’s test. We performed rigorous adjust-
ments for differences in the baseline characteristics of
patients using the propensity score. We calculated the
propensity score using multivariate logistic regression to
model the dichotomous outcome of the surface or the
endovascular group for 803 patients in the sample. The
logistic model demonstrated a sufficient ability to differ-
entiate between the two groups (c statistic = 0.8). We
performed one-to-one matching with the propensity
score using the Greedy-matching macro [18]. After pro-
pensity score matching, the success of the propensity
score modeling was assessed by the standardized differ-
ence, and the balance of the two groups was evaluated
using Student’s t test for continuous variables and the
chi-square test or Fisher’s exact test for categorical vari-
ables. After estimating the propensity scores, we per-
formed a logistic regression analysis to determine the
prognosis factor (mortality, poor outcome). Statistical
analyses were conducted in SAS (version 9.2; SAS Institute,
Inc., Cary, NC, USA). A probability value of P <0.05 was
considered significant.
Results
Characteristics of the study population
Of the 930 OHCA patients entered in the registry be-
tween January 2007 and December 2012, 803 were in-
cluded in the analysis. Of these patients, 559 exclusively
underwent surface cooling and the remaining 244 pa-
tients underwent endovascular cooling (Figure 1). In the
surface cooling group, a cooling mattress (Blanketrol®;
CSZ, Louisville, CO, USA or Medi-Therm®; Gaymar,
Orchard Park, NY, USA) was the most commonly used
device (n = 298, 53.3%), followed by a hydrogel pad
(Arctic Sun®; Medivance Corp, Louisville, CO, USA)
(n = 152, 27.2%) and a cooling body wrap (Blanketrol®
or Medi-Therm®) (n = 77, 13.8%). Multiple surface cooling
devices were used in 32 patients. All endovascular cooling
groups used heat-exchange catheters with inflatable bal-
loons at the tip (Thermogard XP®; Zoll, Chelmsford, MA,USA). Figure 2 presents the choice of methods and neuro-
logic outcomes for each hospital. The baseline characteris-
tics of the study patients, according to the cooling
method, are presented in Table 1.
No differences in age, sex or underlying disease were
observed between the two groups. However, patients re-
ceiving endovascular cooling were significantly more
likely to be witnessed during cardiac arrest, to display an
increased bystander cardiopulmonary resuscitation rate
and to exhibit a greater number of shockable rhythms
than surface cooling patients (72.5% vs. 65.2%, P = 0.04,
41.2% vs. 27.9%, P <0.01 and 30.6% vs. 22.5%, P = 0.02
respectively). More patients in the endovascular cooling
group experienced spontaneous breathing and motor re-
sponse immediately after return of spontaneous circula-
tion compared with the surface cooling group (54.2% vs.
35.8%, P <0.01 and 21.9% vs. 14.9%, P = 0.12 respect-
ively). The number of patients treated by TH during the
study period was significantly larger in the hospitals of
the endovascular cooling group than in the hospitals
of the surface cooling group (135.6 ± 50.0 vs. 70.4 ± 55.2,
P <0.01).
Outcomes for unmatched patients
Table 2 presents the cooling efficacy, adverse events and
neurological outcomes according to the cooling methods
in the overall cohort. Induction time and rewarming
time were not associated with the cooling method; how-
ever, a rewarming time that was slower than the median
time (≥720 minutes) was significantly associated with
endovascular cooling (P = 0.04).
More adverse events, such as overcooling, arrhythmia,
hyperglycemia or hypotension in the cooling phase and
hyperthermia and arrhythmia in the rewarming phase,
occurred in the surface cooling group, which was signifi-
cantly associated with a poor neurological outcome at
hospital discharge (odds ratio (OR): 1.58, 95% confi-
dence interval (CI): 1.15 to 2.19, P <0.01) (Table 3).
The results of the multivariable analysis are illustrated
in Table 3. Using logistic regression and adjusting for
potential outcome predictors (including the cooling
method, sex, age, underlying disease, cardiopulmonary
resuscitation variables, variables after return of spontan-
eous circulation and hospital TH volume), we observed
that the surface cooling method was not an independent
predictor of poor neurological outcome (OR: 1.46, 95%
CI: 0.81 to 2.63, P = 0.21).
Characteristics of patients matched for propensity scores
After propensity score matching was performed for the
entire population, 180 matched pairs of patients were
available (Table 1, after propensity matching). In the
matched cohorts, no significant differences between
both groups for any of the covariates were noted.
Figure 2 Choice of cooling methods and neurologic outcome for each hospital. Stacked bars indicate the number of cooling patients in
each enrolled hospital; endovascular cooling (shaded bars) and surface cooling (unshaded bars). The points and connecting line indicate the
percentages of good neurological outcome in each enrolled hospital.
Figure 1 Flow chart for the inclusion of study patients. Parentheses indicate a percentage. CPC, Cerebral Performance Category; TH,
therapeutic hypothermia.
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Table 1 Baseline characteristics of the patients in the overall cohort and in the propensity-matched cohort










(N = 803) (n = 559) (n = 244) (N = 360) (n = 180) (n = 180)
Demographic characteristics
Male 561 (69.9) 391 (70.0) 170 (69.7) 0.94 −0.65 244 (67.8) 119 (66.1) 125 (69.4) 0.50 7.06
Age (years) 56.9 ± 16.1 57.2 ± 16.1 56.0 ± 16.0 0.32 6.10 55.7 ± 16.9 56.0 ± 17.2 55.5 ± 16.6 0.78 2.40
Underlying disease
Ischemic heart disease 102 (12.7) 71 (12.7) 31 (12.7) 1.00 0.00 48 (13.3) 23 (12.8) 25 (13.9) 0.76 3.23
Cerebrovascular disease 33 (4.1) 24 (4.3) 9 (3.7) 0.69 −3.06 18 (5.0) 11 (6.1) 7 (3.9) 0.33 −10.11
Hypertension 270 (33.6) 192 (34.4) 78 (32.0) 0.51 −5.10 119 (33.1) 61 (33.9) 58 (32.2) 0.74 −3.61
Diabetes mellitus 180 (22.4) 118 (21.1) 62 (25.4) 0.18 10.19 86 (23.9) 44 (24.4) 42 (23.3) 0.81 −2.58
Lung disease 51 (6.4) 37 (6.6) 14 (5.7) 0.64 −3.75 21 (5.8) 11 (6.1) 10 (5.6) 0.82 −2.13
Renal disease 52 (6.5) 33 (5.9) 19 (7.8) 0.32 7.53 27 (7.5) 14 (7.8) 13 (7.2) 0.84 −2.28
CPR variables
Witnessed 541 (67.5) 364 (65.2) 177 (72.5) 0.04 15.81 244 (67.8) 122 (67.8) 122 (67.8) 1.00 0.00
Bystander CPR 245 (31.9) 151 (27.9) 94 (41.2) <0.01 28.25 88 (26.8) 42 (25.6) 46 (27.9) 0.64 5.20
Shockable rhythm 199 (24.9) 125 (22.5) 74 (30.6) 0.02 18.42 85 (23.9) 38 (21.4) 47 (26.4) 0.26 11.74
Anoxic timec (minutes) 32.6 ± 18.4 32.8 ± 18.9 32.1 ± 17.4 0.65 3.10 32.8 ± 19.1 32.7 ± 20.1 32.9 ± 18.1 0.93 −0.84
Cardiac cause 498 (62.0) 335 (59.9) 163 (66.8) 0.07 14.36 231 (64.2) 114 (63.3) 117 (65.0) 0.74 3.55
Variables after ROSC
STEMI 73 (9.1) 48 (5.6) 25 (10.3) 0.45 5.81 27 (7.5) 14 (7.8) 13 (7.2) 0.84 −2.28
Spontaneous breathing 325 (41.4) 196 (35.8) 129 (54.2) <0.01 37.63 182 (51.7) 94 (53.4) 88 (50.0) 0.52 −6.81
Motor response 135 (17.0) 83 (14.9) 52 (21.9) 0.02 18.14 71 (19.9) 37 (20.7) 34 (19.1) 0.71 −4.01
Pupil light reflex 343 (43.4) 238 (42.9) 105 (44.7) 0.64 3.63 174 (49.7) 88 (50.0) 86 (49.4) 0.91 −1.20
Hospital variable
TH volume 90.2 ± 61.5 70.4 ± 55.2 135.6 ± 50.0 <0.01 −99.46 129.4 ± 55.9 130.1 ± 58.5 128.6 ± 53.3 0.80 2.16
Continuous variables are presented as the mean ± standard deviation. Parentheses indicate a percentage. CPR, cardiopulmonary resuscitation; ROSC, return of
spontaneous circulation; STEMI, ST segment elevation myocardial infarction; TH, therapeutic hypothermia. aStandardized difference between the surface group
and endovascular group before propensity score matching.
bStandardized difference between the surface group and endovascular group after propensity score matching. cAnoxic time is the time from cardiac arrest to
return of spontaneous circulation.
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In the outcome analysis (Table 4), we observed no sig-
nificant difference in the neurological outcomes between
the surface cooling and endovascular cooling groups.
The use of surface cooling methods was not a predictor
for poor neurological outcome or hospital mortality
(OR: 1.26, 95% CI: 0.81 to 1.96, P = 0.31 and OR: 0.85,
95% CI: 0.55 to 1.30, P = 0.44 respectively). With regard
to cooling efficacy, both groups spent a similar amount
of time attaining the target temperature, but the sur-
face cooling group rewarmed at a more rapid rate
(625.0 ± 34.9 minutes vs.741.3 ± 32.3 minutes, P <0.01).
The rates of some adverse events were significantly in-
creased in the surface cooling group compared with
the endovascular cooling group. The ORs of surface
cooling for overcooling, rebound hyperthermia and
rewarming-related hypoglycemia and hypotension were2.56 (95% CI: 1.32 to 4.99, P = 0.01), 2.49 (95% CI: 1.15 to
5.40, P = 0.02), 2.02 (95% CI 1.04 to 3.94, P = 0.04) and 1.68
(95% CI: 1.04 to 2.71, P = 0.04), respectively (Figure 3).
Comparisons between hydrogel pads and catheter balloons
Multiple types of surface cooling methods were included
in this study, whereas a heat-exchange catheter with
saline-circulating balloons was the only endovascular
cooling method device. To eliminate the influence of
technological diversity, only one type of modern surface
cooling device using hydrogel pads was compared with
the endovascular cooling device. Similar to the preceding
analysis, propensity score matching was performed in
patients treated with both devices. Ultimately, 59
matched pairs of patients were available. There were no
significant differences in hospital mortality and poor
neurological outcome (Table 5).
Table 2 Cooling efficacy, complication and neurological outcomes between the surface cooling and endovascular
cooling groups
Total (N = 803) Surface group Endovascular group P value
(n = 559) (n = 244)
Time variables
Induction time (minutes) 231.1 ± 9.1 240.1 ± 11.8 211.1 ± 12.9 0.10
≥165 minutes (cutoff value: median) 395 (51.1) 269 (50.3) 126 (52.9) 0.50
Rewarming time (minutes) 745.9 ± 17.8 744.3 ± 23.1 749.5 ± 25.7 0.88
≥720 minutes (cutoff value: median) 353 (50.4) 232 (47.8) 121 (56.3) 0.04
Adverse events in the cooling phase
Overcooling 151 (18.8) 131 (23.5) 20 (8.2) <0.01
Bradycardia 106 (13.3) 84 (15.1) 22 (9.0) 0.02
Tachycardia 99 (12.4) 81 (14.5) 18 (7.5) 0.01
Hypokalemia 234 (29.3) 170 (30.6) 64 (26.3) 0.22
Hyperglycemia 369 (46.1) 295 (53.0) 74 (30.3) <0.01
Bleeding 26 (3.3) 20 (3.6) 6 (2.5) 0.42
Hypotension 280 (35.0) 209 (37.6) 71 (29.1) 0.02
Adverse events in the rewarming phase
Hyperthermia 80 (10.7) 67 (13.0) 13 (5.6) <0.01
Arrhythmia 42 (5.7) 37 (7.2) 5 (2.2) 0.01
Hyperkalemia 56 (7.5) 39 (7.6) 17 (7.4) 0.91
Hypoglycemia 73 (9.8) 55 (10.7) 18 (7.8) 0.22
Bleeding 12 (1.6) 7 (1.4) 5 (2.2) 0.53
Hypotension 180 (24.2) 133 (25.9) 47 (20.4) 0.10
Adverse events in critical care
Sepsis 59 (7.5) 40 (7.3) 19 (7.8) 0.80
Pneumonia 283 (35.6) 191 (34.6) 92 (38.0) 0.36
Neurological outcome
Hospital mortality 310 (38.6) 218 (39.0) 92 (37.7) 0.73
Poor neurological outcome 574 (71.5) 416 (74.4) 158 (64.7) 0.01
Continuous variables are presented as the mean ± standard error. Parentheses indicate a percentage.
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group rewarmed at a slower rate (923.2 ± 61.1 minutes
vs. 697.3 ± 67.7 minutes, P <0.01), and the OR of the
hydrogel pad group for sepsis was 0.11 (95% CI: 0.01 to
0.89, P = 0.04). Overcooling, rebound hyperthermia and
rewarming-related hypoglycemia and hypotension were
not associated with the use of hydrogel pads.
Discussion
We compared neurological outcomes, efficacies and
adverse events between surface and endovascular cool-
ing techniques. Our multicenter, retrospective, observa-
tional, registry-based study indicated that the rates of
poor neurological outcome and hospital mortality were
similar in both groups; however, the incidences of cer-
tain adverse events were more common in the surface
cooling group.Our findings are consistent with those published in
the literature. Gillies and colleagues reported no differ-
ence in hospital mortality and neurological outcomes be-
tween the two groups; in addition, endovascular cooling
provides improved temperature management compared
with surface cooling as well as a more favorable compli-
cation profile [12]. However, this study only compared
the use of endovascular cooling using automatic
temperature control feedback with ice bags without the
aid of temperature feedback regulation. In a single-
center observational study, similar survival-to-hospital
discharge and comparable neurological outcomes were
observed in the endovascular cooling group using cath-
eter balloons and in the surface cooling group using
hydrogel pads [13]. Recently, one randomized controlled
trial reported that invasive endovascular cooling has
advantages over surface cooling using hydrogel pads
Table 3 Independent predictors for poor neurological outcome and hospital discharge in the unmatched cohort
Poor neurological outcome Hospital mortality
OR 95% CI P value Adjusted OR 95% CI P value OR 95% CI P value Adjusted OR 95% CI P value
Method
Surface cooling 1.58 1.15 to 2.19 0.01 1.46 0.81 to 2.63 0.21 1.06 0.78 to 1.44 0.73 0.78 0.50 to 1.21 0.26
Demographic characteristics
Male 0.50 0.35 to 0.72 <0.01 0.63 0.37 to 1.06 0.08 0.56 0.41 to 0.76 <0.01 0.67 0.47 to 0.96 0.03
Age 1.04 1.03 to 1.05 <0.01 1.04 1.02 to 1.06 <0.01 1.02 1.01 to 1.03 <0.01 1.02 1.00 to 1.03 0.01
≥57 years old 3.04 2.20 to 4.20 <0.01 1.92 1.44 to 2.57 <0.01
Underlying disease
Ischemic heart disease 0.77 0.50 to 1.20 0.25 0.85 0.55 to 1.31 0.46
Cerebrovascular disease 2.30 0.88 to 6.03 0.09 1.96 0.98 to 3.96 0.06
Hypertension 1.63 1.16 to 2.28 0.01 1.29 0.72 to 2.31 0.40 1.29 0.95 to 1.73 0.10
Diabetes mellitus 2.59 1.67 to 4.00 <0.01 1.68 0.86 to 3.29 0.13 1.94 1.39 to 2.72 <0.01 1.54 1.02 to 2.33 0.04
Lung disease 5.02 1.79 to 14.09 <0.01 3.09 0.82 to 11.65 0.10 1.22 0.69 to 2.17 0.49
Renal disease 5.13 1.83 to 14.41 <0.01 1.48 0.43 to 5.13 0.54 2.11 1.20 to 3.72 0.01 1.09 0.56 to 2.15 0.80
CPR variables
Witnessed 0.36 0.25 to 0.53 <0.01 0.58 0.34 to 1.01 0.05 0.43 0.31 to 0.58 <0.01 0.60 0.42 to 0.85 0.01
Bystander CPR 1.96 1.41 to 2.72 <0.01 1.22 0.72 to 2.04 0.46 0.78 0.57 to 1.07 0.12
Shockable rhythm 0.51 0.37 to 0.71 <0.01 0.51 0.30 to 0.87 0.01 0.33 0.22 to 0.48 <0.01 0.62 0.39 to 0.99 0.05
Anoxic timea 1.03 1.02 to 1.04 <0.01 1.05 1.03 to 1.06 <0.01 1.02 1.01 to 1.03 <0.01 1.02 1.01 to 1.03 <0.01
≥30 minutes 2.64 1.92 to 3.63 <0.01 1.83 1.37 to 2.45 <0.01
Cardiac cause 0.14 0.09 to 0.22 <0.01 0.19 0.11 to 0.35 <0.01 0.37 0.28 to 0.50 <0.01 0.55 0.38 to 0.79 <0.01
Variables after ROSC
STEMI 0.35 0.21 to 0.57 <0.01 0.78 0.38 to 1.60 0.49 0.66 0.39 to 1.12 0.12
Spontaneous breathing 0.19 0.14 to 0.27 <0.01 0.41 0.25 to 0.67 <0.01 0.27 0.20 to 0.38 <0.01 0.46 0.32 to 0.68 <0.01
Motor response 0.10 0.07 to 0.15 <0.01 0.23 0.13 to 0.41 <0.01 0.16 0.09 to 0.28 <0.01 0.45 0.24 to 0.85 0.01
Pupil light reflex 0.11 0.07 to 0.15 <0.01 0.26 0.16 to 0.42 <0.01 0.21 0.15 to 0.30 <0.01 0.43 0.30 to 0.64 <0.01
Hospital variable
TH volume 1.00 0.99 to 1.00 <0.01 1.00 1.00 to 1.01 0.21 1.00 0.99 to 1.00 <0.01 1.00 1.00 to 1.00 0.34
≥60 0.63 0.46 to 0.86 <0.01 0.77 0.58 to 1.03 0.08
CI, confidence interval; CPR, cardiopulmonary resuscitation; OR, odds ratio; ROSC, return of spontaneous circulation; STEMI, ST segment elevation myocardial infarction; TH, therapeutic hypothermia. aAnoxic time is the










Table 4 Logistic regression analysis of the matched cohort for outcomes, efficacies and complications
Surface cooling group Endovascular cooling group Odds ratio 95% confidence
interval
P value
(n = 180) (n = 180)
Time variables
Induction time (minutes) 235.3 ± 18.0 209.4 ± 15.4 1.13 0.79 to 1.62 0.51
≥173.5 minutes (cutoff value: median) 88 (50.0) 89 (50.0) 1.00 0.66 to 1.52 1.00
Rewarming time (minutes) 625.0 ± 34.9 741.3 ± 32.3 0.50 0.34 to 0.73 <0.01
≥660 minutes (cutoff value: median) 68 (40.7) 103 (65.2) 0.37 0.23 to 0.58 <0.01
Adverse events in the cooling phase
Overcooling 32 (17.8) 14 (7.8) 2.56 1.32 to 4.99 0.01
Bradycardia 16 (9.0) 15 (8.3) 1.09 0.52 to 2.27 0.83
Tachycardia 16 (8.9) 14 (7.9) 1.14 0.54 to 2.42 0.73
Hypokalemia 59 (32.8) 45 (25.1) 1.45 0.92 to 2.30 0.11
Hyperglycemia 104 (57.8) 58 (32.2) 1.54 1.00 to 2.36 0.05
Bleeding 3 (1.7) 5 (2.9) 0.59 0.14 to 2.49 0.45
Hypotension 72 (40.2) 58 (32.2) 1.42 0.92 to 2.18 0.12
Adverse events in the rewarming phase
Hyperthermia 23 (13.5) 10 (5.9) 2.49 1.15 to 5.40 0.02
Arrhythmia 5 (2.9) 5 (3.0) 0.98 0.28 to 3.46 0.98
Hyperkalemia 19 (11.1) 14 (8.2) 1.39 0.67 to 2.88 0.37
Hypoglycemia 28 (16.4) 15 (8.8) 2.02 1.04 to 3.94 0.04
Bleeding 1 (0.6) 3 (1.8) 0.32 0.03 to 3.12 0.33
Hypotension 56 (32.6) 38 (22.4) 1.68 1.04 to 2.71 0.04
Adverse events in critical care
Sepsis 13 (7.2) 15 (8.4) 0.85 0.39 to 1.84 0.68
Pneumonia 57 (31.8) 63 (35.4) 0.85 0.55 to 1.32 0.48
Neurological outcome
Hospital mortality 62 (34.4) 69 (38.3) 0.85 0.55 to 1.30 0.44
Poor neurological outcome 126 (70.0) 117 (65.0) 1.26 0.81 to 1.96 0.31
Continuous variables are presented as the mean ± standard error. Parentheses indicate a percentage.
Figure 3 Odds ratio for each adverse event for surface cooling. Each plot represents the odds ratio and 95% confidence interval.
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Table 5 Logistic regression analysis of the matched cohort of hydrogel pads and catheter balloons for outcomes,
efficacies and complications
Hydrogel pads Catheter balloons Odds ratio 95% confidence interval P value
(n = 59) (n = 59)
Time variables
Induction time (minutes) 188.1 ± 22.6 243.4 ± 35.3 0.73 0.39 to 1.39 0.34
≥160.0 minutes (cutoff value: median) 26 (45.6) 32 (56.1) 0.66 0.31 to 1.37 0.26
Rewarming time (minutes) 923.2 ± 61.1 697.3 ± 67.7 3.23 1.60 to 6.52 <0.01
≥720 minutes (cutoff value: median) 39 (78.0) 23 (43.40) 4.62 1.95 to 10.95 <0.01
Adverse events in the cooling phase
Overcooling 8 (13.56) 9 (15.25) 0.87 0.31 to 2.44 0.79
Bradycardia 9 (15.25) 7 (11.86) 1.34 0.46 to 3.86 0.59
Tachycardia 7 (11.86) 11 (19.30) 0.56 0.20 to 1.57 0.27
Hypokalemia 16 (27.12) 13 (22.41) 1.29 0.56 to 2.99 0.56
Hyperglycemia 34 (57.63) 27 (45.76) 1.61 0.78 to 3.34 0.20
Bleeding 3 (5.08) 3 (5.45) 0.93 0.18 to 4.81 0.93
Hypotension 25 (42.37) 17 (28.81) 1.82 0.85 to 3.90 0.13
Adverse events in the rewarming phase
Hyperthermia 7 (12.73) 1 (1.82) 7.88 0.94 to 66.33 0.06
Arrhythmia 4 (7.41) 3 (5.66) 1.33 0.28 to 6.27 0.72
Hyperkalemia 6 (11.11) 6 (10.91) 1.02 0.31 to 3.39 0.97
Hypoglycemia 8 (14.81) 2 (3.64) 4.61 0.93 to 22.81 0.06
Bleeding 2 (3.70) 2 (3.85) 0.96 0.13 to 7.09 0.97
Hypotension 19 (35.19) 12 (21.82) 1.95 0.83 to 4.55 0.13
Adverse events in critical care
Sepsis 1 (1.69) 8 (13.79) 0.11 0.01 to 0.89 0.04
Pneumonia 17 (28.81) 22 (37.93) 0.66 0.31 to 1.44 0.30
Neurological outcome
Hospital mortality 26 (44.07) 22 (37.29) 1.33 0.63 to 2.77 0.45
Poor neurological outcome 45 (76.27) 40 (67.80) 1.53 0.68 to 3.44 0.31
Continuous variables are presented as the mean ± standard error. Parentheses indicate a percentage.
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techniques did not result in a different outcome [14].
There are known differences between surface and
endovascular cooling. Some of the literature has re-
ported a significant increase in the rate of the occur-
rence of shivering in patients treated with surface
cooling devices. Surface cooling is known to cause
shivering, resulting in possible sympathetic activation
[19-22]. If shivering is not controlled, the body temperature
will not decrease, despite cooling. In contrast, hypothermia
induced by core cooling with cardiopulmonary bypass pro-
duces sympathetic inhibition in anesthetized rabbits [23].
In our study, paralyzing agents were generally used but
were selected case by case. Therefore, we could not include
shivering as a meaningful adverse event. Surface cooling
techniques using non-invasive devices are easy to imple-
ment and have advantages, such as the lack of therequirement for puncturing an additional main vessel. This
feature may reduce complications and infections in resus-
citated patients, who represent a highly vulnerable popula-
tion [6]. Endovascular cooling involves the insertion of a
large gauge catheter into the vena cava, which is an inva-
sive and time-consuming procedure [10,14]. In contrast,
surface cooling techniques can be labor intensive for the
nursing staff and might prevent access to the patient [12].
Despite these findings, the best method for treatment in a
clinical setting has not been identified.
Various possible factors might influence the neuro-
logical outcome of cardiac arrest patients treated with
TH. The first possible factor is time to target tem-
perature. Evidence suggests that the time to TH has an
important impact on the outcome [8,24,25]. Given that
surface cooling increases the rate of shivering [19-22]
and some simple surface devices are less effective at
Oh et al. Critical Care  (2015) 19:85 Page 10 of 12cooling than endovascular cooling [26], the time needed
from the start of cooling to achieve the target tem-
perature was significantly increased for surface cooling
[14]. The time required to initiate treatment is another
factor to be considered when comparing endovascular
cooling with surface cooling. Inserting an endovascular
device requires the availability of medical personnel,
whereas surface cooling can be initiated quickly by the
nursing staff [27]. In contrast, although the use of early,
prehospital cooling reduced the core temperature by the
time of hospital arrival and reduced the time to reach
34°C, it did not improve survival or functional status
among patients resuscitated from OHCA in a recent
randomized clinical trial of the prehospital induction
of mild hypothermia [28]. Second, surface cooling is as-
sociated with failure to achieve the target temperature
(33°C) and with overcooling [29,30]. A new randomized
trial reported no significant difference between a near-
normal temperature (36°C) and induced hypothermia
(33°C) [31]. One interpretation of these results is that
active prevention of hyperthermia is more important
than a strict lower temperature or early induction in car-
diac arrest patients. This finding potentially explains
why the surface cooling method, which is associated to a
greater extent with poor temperature management, is
not inferior to the core cooling method with respect to
neurological outcomes.
Interestingly, a higher rate of some adverse events in
the surface cooling group was observed compared with
the endovascular cooling group in the matched cohort.
However, many wide confidence intervals reflected the
small sample size; thus, these results may not show a
significant difference between the two groups.
Patients receiving surface cooling might be at in-
creased risk of overcooling and rebound hyperthermia
as a result of problems with the equilibration of the per-
ipheral temperature with the core body temperature
[29,32]. Hypoglycemia is also a well-known rewarming-
related adverse event [33,34], and more rapid rewarming
and rebound hyperthermia in the surface cooling group
might lead to these rewarming-related adverse events.
The application of external heat may cause peripheral
vasodilation and venous pooling, leading to relative
hypovolemia and hypotension [35]. In a previous report
regarding complications of TH, bleeding and sepsis that
occurred after invasive procedures, such as those using
intravascular devices for cooling, as well as sustained
hyperglycemia were associated with increased mortality
[36]. However, these adverse events that were known to
be associated with worse outcomes were not associated
with specific cooling methods in our study.
Several of our findings deserve further mention. First,
in the unmatched cohort, patients receiving endovascu-
lar cooling exhibited good clinical variables and werealso more likely to be treated in a high TH volume hos-
pital. This finding was significantly associated with good
neurological outcomes. We therefore performed one-to-
one matching using the propensity score. After propen-
sity score matching, the two groups were balanced.
Second, we compared all of the surface cooling devices,
including hydrogel pads and many of the simple water
circulating blankets/wraps, with endovascular cooling
devices. This study is the first to compare overall surface
cooling devices with endovascular cooling devices. Endo-
vascular cooling is a unique technique that uses an auto-
matic temperature control feedback system. However,
surface cooling devices are diverse. Hydrogel pads differ
from other cooling blankets by producing higher cold
fluid flow rates, utilizing conductive, adherent gel pads
and implementing a precise temperature feedback-
control mechanism. These factors might allow for a
more rapid induction of cooling and improved control
of temperature during hypothermia maintenance, as well
as rewarming, than other cooling blankets. However, in
a recent study comparing hydrogel pads and a conven-
tional standard cooling blanket, no differences in the in-
cidence of complications during TH and neurological
outcomes were reported between the two groups [37]. In
our study, more than two-thirds of patients who were
cooled by these other devices were included in the sur-
face cooling group. Nevertheless, no difference was ob-
served in the neurological outcomes between the two
groups, while some adverse events were associated with
the surface cooling group. However, when we confine
the surface cooling device to hydrogel pads, these ad-
verse events were no longer observed. The hydrogel pad
group rewarmed more slowly but within the range of the
targeted rewarming rate (0.2 to 0.3°C/hour). The OR of
the hydrogel pad group for sepsis had a wide CI (0.01 to
0.89), which implies low statistical power due to limited
numbers of matched patients. Our results may indicate
that some adverse events in the surface cooling group
were not the result of differences between both methods,
but were caused by an inability to precisely control the
body temperature. Furthermore, these differences did
not have an effect on the neurological outcome.
Limitations
The results of this study should be interpreted in the
context of several limitations. A major limitation of this
study was the possibility of selection bias and reporting
bias. Although we tried to mimic randomization, there
was an inevitable risk of bias because our study was a
retrospective, registry-based multicenter study. Add-
itionally, our retrospective registry did not include po-
tential confounding factors such as cardiac intervention,
hemodynamic status, time of endovascular catheter in-
sertion and various complications regarding vascular
Oh et al. Critical Care  (2015) 19:85 Page 11 of 12access. Because this limitation can lead to a skewed per-
ception of the adverse event rates between the two
groups, our results must be interpreted with caution. Al-
though we adjusted for hospital TH volume as a poten-
tial confounder, the majority of hospitals used either
surface or endovascular cooling, and we did not adjust
for other hospital factors. Variable TH protocols or dif-
ferences in care among hospitals may therefore affect
the incidence of adverse events, time variables and out-
come. Although this was a multicenter registry study,
the sample size was relatively small after we performed
one-to-one matching, and some wide ORs reflected low
statistical power. Finally, in our registry, only one type of
endovascular device was used whereas the surface cool-
ing group included various devices.Conclusions
In the matched cohort, no significant differences in the
rates of poor neurological outcomes and hospital mor-
tality were observed between the surface cooling and
endovascular cooling groups. Although overcooling,
rebound hyperthermia, rewarming-related hypoglycemia
and rewarming-related hypotension were significantly
increased in the surface cooling group compared with
the endovascular cooling group, these complications
were not associated with the surface cooling method
using hydrogel pads.Key messages
 No significant difference in neurological outcome
and hospital mortality was observed between the
surface and endovascular cooling methods.
 Overcooling, rebound hyperthermia, rewarming-
related hypoglycemia and rewarming-related
hypotension were significantly increased in the surface
cooling group compared with the endovascular
cooling group.
 These adverse events of surface cooling were not
observed in the modern surface cooling method
using hydrogel pads.Additional file
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